The study of neurotransmitter interactions with PET and SPECT using pharmacological challenge paradigms;Erfassung yon neurotransmitterinteraktionen mit PET und SPECT durch pharmakologische challenge-paradigmen

Nervenarzt

Volumn 71, Issue 1, 2000, Pages 9-18

  Schlosser R ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Interactions Psychopharmacology; Neurotransmitter; PET; SPECT

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CATECHOLAMINE; DIAGNOSTIC AGENT; PSYCHOTROPIC AGENT;

CHOLINERGIC SYSTEM; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; HUMAN; NEUROCHEMISTRY; NEUROMODULATION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMOCORTICAL TRACT; ANIMAL; BRAIN; BRAIN MAPPING; COGNITIVE DEFECT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; FEEDBACK SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING; SYNAPTIC TRANSMISSION;

ANIMALS; BRAIN; BRAIN MAPPING; CATECHOLAMINES; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DOPAMINE; FEEDBACK; HUMANS; NEUROTRANSMITTER AGENTS; PSYCHOTROPIC DRUGS; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033621972     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050002     Document Type: Review

References (59)

1. Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9:357-381
2. Andreasen NC, Carson R, Diksic M et al. (1988) Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. Schizophr Bull 14:471-484
3. Arora RC, Meltzer HY (1991) Serotonin 2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 85:19-29
4. Boschert U, Amara DA, Segu L, Hen R (1994) The mouse 5-hydroxytryptamine 1B receptor is localized predominantly on axon terminals. Neurosci 58:167-182
5. Breier A, Adler CM, Weisenfeld N et al. (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29:142-147
6. Breier A, Su TP, Saunders R et al. (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574
7. Carlsson M, Carlsson A (1990) Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 16:425-432
8. Consolo S, Ladinsky H, Tirelli AS, Crunelli V, Samanin R, Garattini S (1979) Increase in rat striatal acetylcholine content by d-fenfluramine, a serotonin releaser. Life Sci 25:1975-1981
9. Coppens HJ, Slooff CJ, Paans AM, Wiegman T, Vaalburg W, Korf J (1991) High central D2-dopamine receptor occupancy as assessed with positron emission tomography. Biol Psychiatry 29:629-634
10. Coyle JT, Snyder SH (1969) Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 166:809-811
11. Dewey SL, Brodie JD, Fowler JS et al. (1990) Positron emission tomography (PET) studies of dopaminergic/cholinergic interactions in the baboon brain. Synapse 6:321-327
12. Dewey SL, Chaurasia CS, Chen CE et al. (1997) GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 25:393-398
13. Dewey SL, Logan J, Wolf AP, Brodie JD, Angrist B, Fowler JS, Volkow ND (1991 ) Amphetamine induced decreases in (18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). Synapse 7:324-327
14. Dewey SL, Morgan AE, Ashby CR et al. (1998) A novel strategy for the treatment of cocaine addiction. Synapse 30:119-129
15. Dewey SL, Smith GS, Logan J et al. (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15(1 Pt 2):821-829
16. Dewey SL, Smith GS, Logan J, Brodie JD (1993) Modulation of central cholinergic activity by GABA and serotonin: PET studies with 11C-benztropine in primates. Neuropsychopharmacology 8:371-376
17. Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP (1993) Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356
18. Dewey SL, Smith GS, Logan J et al. (1993) Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 90:11816-11820
19. Dewey SL, Smith GS, Logan J et al. (1992) GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci 12:3773-3780
20. Dewey SL, Wolf A, Fowler J et al. (1988) The effects of central cholinergic blockade on 18F-N-methylspiroperidol binding in the human brain. XVI CINP Congress 96:162
21. Endres CJ, Kolachana BS, Saunders RC et al. (1997) Kinetic modeling of [11 C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab 17:932-942
22. Farde L, Hall H, Pauli S, Halldin C (1995) Variability in D2-dopamine receptor density and affinity: a PET study with [11 C]raclopride in man. Synapse 20:200-208
23. Farde L, Wiesel F, Hall H, Halldin C, Stone-Elander S, Sedvall G (1987) No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 44:672-672
24. Grace AA (1991 ) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neurosci 41:1-24
25. Grace AA (1992) The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl 36:91-131
26. Hirsch SR, Weinberger DR (1995) Schizophrenia. Blackwell Science, Oxford
27. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476
28. Krebs MO, Trovero F, Desban M, Gauchy C, Glowinski J, Kernel ML (1991) Distinct presynaptic regulation of dopamine release through NMDA receptors in striosome-and matrix-enriched areas of the rat striatum. J Neurosci 11:1256-1262
29. Laruelle M, Abi-Dargham A, van-Dyck CH et al. (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240
30. Laruelle M, Abi-Dargham A, van Dyck CH et al. (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190
31. Laruelle M, D'Souza CD, Baldwin RM et al. (1997) Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162-174
32. Laruelle M, Iyer RN, al-Tikriti MS et al. (1997) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14
33. Logan J, Dewey SL, Wolf AP et al. (1991) Effects of endogenous dopamine on measures of [18F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 9:195-207
34. Logan J, Volkow ND, Fowler JS et al. (1994) Effects of blood flow on [11 C]raclopride binding in the brain: model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 14:995-1010
35. Mach RH, Nader MA, Ehrenkaufer RL, Line SW, Smith CR, Gage HD, Morton TE (1997) Use of positron emission tomography to study the dynamics of psychostimulant-induced dopamine release. Pharmacol Biochem Behav 57:477-486
36. McGeer PL, Eccles JC, McGeer EG (1987) Molecular neurobiology of the mammalian brain. Plenum, New York
37. Meltzer HY (1987) Biological studies in schizophrenia. Schizophr Bull 13:77-111
38. Mukherjee J, Yang ZY, Brown T, Roemer J, Cooper M (1996) 18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. Life Sci 59:669-678
39. Pozzi L, Trabace L, Invernizzi R, Samanin R (1995) Intranigral GR-113808, a selective 5-HT4 receptor antagonist, attenuates morphine-stimulated dopamine release in the rat striatum. Brain Res 692:265-268
40. Price JC, Mathis CA, Lopresti DH, Mason NS, Drevets W (1998) Dose dependency of amphetamine-induced 11C-raclopride binding parameter changes. Neuroimage 3:A12
41. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC (1994) Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51:124-131
42. Schlegel S, Steinert H, Bockisch A, Hahn K, Schloesser R, Benkert O (1994) Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. Eur Arch Psychiatry Clin Neurosci 244:49-51
43. Schlösser R, Brodie JD, Dewey SL et al. (1998) Long-term stability of neurotransmitter activity investigated with 11C-raclopride PET. Synapse 28:66-70
44. Schlösser R, Schlegel S (1995) D2-receptor imaging with [123I]IBZM and single photon emission tomography in psychiatry: a survey of current status. J Neural Transm 99:173-185
45. Schlösser R, Schlegel S, Hiemke C, Nickel O, Bockisch A, Rao ML, Hahn K (1997) 1231-IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects. Psychiatry Res Neuroimaging Section 75:103-114
46. Schloesser R, Simkowitz P, Bartlett EJ, Wolkin A, Smith GS, Dewey SL, Brodie JD (1996) The study of neurotransmitter interactions using positron emission tomography and functional coupling. Clin Neuropharmacol 19:371-389
47. Smith AD, Bolam JP (1990) The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13:259-265
48. Smith GS, Dewey SL, Brodie JD et al. (1997) Serotonergic modulation of dopamine measured with [11 C]raclopride and PET in normal human subjects. Am J Psychiatry 154:490-496
49. Smith GS, Schloesser R, Brodie JD et al. (1998) Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25
50. Tandon R, Greden JF (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 46:745-753
51. Tandon R, Greden JF, Haskett RF (1993) Cholinergic hyperactivity and negative symptoms: behavioral effects of physostigmine in normal controls. Schizophr Res 9:19-23
52. Verma A, Moghaddam B (1998) Regulation of striatal dopamine release by metabotropic glutamate receptors. Synapse 28:220-226
53. Volkow ND, Fowler JS, Wang GJ et al. (1993) Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 34:609-613
54. Volkow ND, Wang GJ, Fowler JS et al. (1994) Imaging endogenous dopamine competition with [11 C]raclopride in the human brain. Synapse 16:255-262
55. Wang GJ, Volkow ND, Fowler JS et al. (1996) Age associated decrements in dopamine D2 receptors in thalamus and in temporal insula of human subjects. Life Sci 59:PL31-PL35
56. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669
57. Wolkin A, Barouche F, Wolf AP et al. (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905-908
58. Wolkowitz OM, Pickar D (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 148:714-726
59. Wong DF, Wagner HN Jr, Tune LE et al. (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563